S. Zante Greg's most recent trade in Viking Therapeutics Inc was a trade of 7,667 Common Stock, par value $0.00001 per share done . Disclosure was reported to the exchange on July 2, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Viking Therapeutics Inc | S. Zante Greg | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jul 2025 | 7,667 | 172,926 (0%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 27.76 per share. | 02 Jul 2025 | 4,266 | 168,660 (0%) | 0% | 27.8 | 118,428 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 42.69 per share. | 03 Jan 2025 | 45,609 | 169,959 (0%) | 0% | 42.7 | 1,946,993 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 44,533 | 193,901 (0%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 37,200 | 37,200 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 21,667 | 215,568 (0%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 43.32 per share. | 03 Jan 2025 | 4,700 | 165,259 (0%) | 0% | 43.3 | 203,601 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2024 | 51,000 | 153,000 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.52 per share. | 28 Oct 2024 | 51,000 | 281,053 (0%) | 0% | 8.5 | 434,520 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 74.56 per share. | 28 Oct 2024 | 49,672 | 231,381 (0%) | 0% | 74.6 | 3,703,495 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2024 | 26,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.80 per share. | 28 Oct 2024 | 26,000 | 230,053 (0%) | 0% | 5.8 | 150,800 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 77.68 per share. | 28 Oct 2024 | 23,082 | 180,414 (0%) | 0% | 77.7 | 1,793,019 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 75.79 per share. | 28 Oct 2024 | 18,620 | 212,761 (0%) | 0% | 75.8 | 1,411,135 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 78.69 per share. | 28 Oct 2024 | 15,825 | 164,589 (0%) | 0% | 78.7 | 1,245,280 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.77 per share. | 28 Oct 2024 | 12,750 | 199,802 (0%) | 0% | 7.8 | 99,068 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2024 | 12,750 | 0 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 76.94 per share. | 28 Oct 2024 | 9,265 | 203,496 (0%) | 0% | 76.9 | 712,803 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 80.65 per share. | 28 Oct 2024 | 7,967 | 150,572 (0%) | 0% | 80.7 | 642,545 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 79.78 per share. | 28 Oct 2024 | 6,050 | 158,539 (0%) | 0% | 79.8 | 482,665 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2024 | 4,251 | 0 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.68 per share. | 28 Oct 2024 | 4,251 | 204,053 (0%) | 0% | 4.7 | 19,895 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 81.44 per share. | 28 Oct 2024 | 1,206 | 149,366 (0%) | 0% | 81.4 | 98,222 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2024 | 21,667 | 203,188 (0%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 56.96 per share. | 29 Jul 2024 | 12,662 | 190,526 (0%) | 0% | 57.0 | 721,228 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2024 | 6,667 | 181,521 (0%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 57.71 per share. | 29 Jul 2024 | 2,974 | 187,552 (0%) | 0% | 57.7 | 171,630 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 58.71 per share. | 29 Jul 2024 | 500 | 187,052 (0%) | 0% | 58.7 | 29,355 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 74.44 per share. | 03 May 2024 | 45,570 | 192,939 (0%) | 0% | 74.4 | 3,392,445 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.88 per share. | 03 May 2024 | 30,000 | 241,610 (0%) | 0% | 4.9 | 146,400 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 30,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 75.49 per share. | 03 May 2024 | 17,238 | 175,701 (0%) | 0% | 75.5 | 1,301,241 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.68 per share. | 03 May 2024 | 4,249 | 211,610 (0%) | 0% | 4.7 | 19,885 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 4,249 | 4,251 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 73.49 per share. | 03 May 2024 | 3,101 | 238,509 (0%) | 0% | 73.5 | 227,887 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 76.07 per share. | 03 May 2024 | 847 | 174,854 (0%) | 0% | 76.1 | 64,435 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2024 | 31,667 | 223,971 (0%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 83.34 per share. | 27 Mar 2024 | 16,610 | 207,361 (0%) | 0% | 83.3 | 1,384,277 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 31,667 | 212,397 (0%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 85.22 per share. | 01 Mar 2024 | 20,093 | 192,304 (0%) | 0% | 85.2 | 1,712,325 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Zante Greg S. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 155,000 | 155,000 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | Zante S. Greg | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 70,000 | 240,491 (0%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Viking Therapeutics Inc | S. Greg Zante | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.40 per share. | 03 Jan 2024 | 30,889 | 209,602 (0%) | 0% | 17.4 | 537,469 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | S. Greg Zante | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 28,334 | 188,724 (0%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Viking Therapeutics Inc | Zante Greg S. | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.40 per share. | 03 Jan 2024 | 18,233 | 170,491 (0%) | 0% | 17.4 | 317,254 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Zante Greg S. | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 17.90 per share. | 03 Jan 2024 | 15,000 | 180,730 (0%) | 0% | 17.9 | 268,500 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | S. Greg Zante | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.58 per share. | 03 Jan 2024 | 13,872 | 195,730 (0%) | 0% | 18.6 | 257,742 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.07 per share. | 17 Apr 2023 | 7,500 | 156,779 (0%) | 0% | 13.1 | 98,025 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Apr 2023 | 7,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 17 Apr 2023 | 7,500 | 149,279 (0%) | 0% | 20 | 150,000 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.00 per share. | 11 Apr 2023 | 56,295 | 149,279 (0%) | 0% | 18.0 | 1,013,518 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.00 per share. | 11 Apr 2023 | 41,544 | 149,279 (0%) | 0% | 18 | 747,792 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.80 per share. | 11 Apr 2023 | 37,447 | 186,726 (0%) | 0% | 5.8 | 217,193 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Apr 2023 | 37,447 | 26,000 | - | - | Stock Option (right to buy | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.88 per share. | 11 Apr 2023 | 30,000 | 191,021 (0%) | 0% | 4.9 | 146,400 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Apr 2023 | 30,000 | 90,000 | - | - | Stock Option (right to buy | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.80 per share. | 11 Apr 2023 | 14,553 | 205,574 (0%) | 0% | 5.8 | 84,407 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Apr 2023 | 14,553 | 63,447 | - | - | Stock Option (right to buy | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Apr 2023 | 8,500 | 8,500 | - | - | Stock Option (right to buy | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.68 per share. | 11 Apr 2023 | 8,500 | 161,021 (0%) | 0% | 4.7 | 39,780 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.77 per share. | 11 Apr 2023 | 4,097 | 190,823 (0%) | 0% | 7.8 | 31,834 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Apr 2023 | 4,097 | 12,750 | - | - | Stock Option (right to buy) | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Apr 2023 | 3,242 | 16,847 | - | - | Stock Option (right to buy) | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.77 per share. | 11 Apr 2023 | 3,242 | 152,521 (0%) | 0% | 7.8 | 25,190 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 17.00 per share. | 30 Mar 2023 | 131,029 | 147,778 (0%) | 0% | 17.0 | 2,227,821 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2023 | 56,667 | 204,445 (0%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.57 per share. | 30 Mar 2023 | 55,166 | 149,279 (0%) | 0% | 17.6 | 969,267 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.69 per share. | 30 Mar 2023 | 42,000 | 259,057 (0%) | 0% | 7.7 | 322,980 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Mar 2023 | 42,000 | 0 | - | - | Stock Option (right to buy) | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.52 per share. | 30 Mar 2023 | 32,000 | 217,057 (0%) | 0% | 8.5 | 272,640 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Mar 2023 | 32,000 | 0 | - | - | Stock Option (right to buy) | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.77 per share. | 30 Mar 2023 | 30,911 | 178,689 (0%) | 0% | 7.8 | 240,178 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.00 per share. | 30 Mar 2023 | 30,911 | 147,778 (0%) | 0% | 18 | 556,398 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Mar 2023 | 30,911 | 0 | - | - | Stock Option (right to buy) | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.65 per share. | 30 Mar 2023 | 12,250 | 271,307 (0%) | 0% | 4.7 | 56,963 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Mar 2023 | 12,250 | 0 | - | - | Stock Option (right to buy) | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Mar 2023 | 7,500 | 0 | - | - | Stock Option (right to buy) | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.12 per share. | 30 Mar 2023 | 7,500 | 278,807 (0%) | 0% | 4.1 | 30,900 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2022 | 204,000 | 204,000 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2022 | 90,667 | 229,698 (0%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.52 per share. | 30 Dec 2022 | 23,933 | 205,765 (0%) | 0% | 8.5 | 203,909 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.42 per share. | 30 Dec 2022 | 20,708 | 185,057 (0%) | 0% | 8.4 | 174,361 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2022 | 20,233 | 158,728 (0%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.40 per share. | 30 Dec 2022 | 19,697 | 139,031 (0%) | 0% | 9.4 | 185,152 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 53,333 | 145,139 (0%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.62 per share. | 03 Jan 2022 | 8,835 | 136,304 (0%) | 0% | 4.6 | 40,818 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.88 per share. | 03 Jan 2022 | 3,097 | 91,806 (0%) | 0% | 4.9 | 15,113 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Sep 2021 | 6,667 | 96,791 (0%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.50 per share. | 28 Sep 2021 | 2,306 | 94,485 (0%) | 0% | 6.5 | 14,989 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.68 per share. | 19 Jan 2021 | 808 | 89,751 (0%) | 0% | 6.7 | 5,397 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 78,000 | 78,000 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 64,667 | 86,563 (0%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 6,783 | 93,346 (0%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.80 per share. | 04 Jan 2021 | 2,787 | 90,559 (0%) | 0% | 5.8 | 16,165 | Common Stock, par value $0.00001 per share |